EU regulators back Lilly’s blockbuster RA pill
Pill could generate $2 billion sales.
X
EU regulators back Lilly’s blockbuster RA pill
https://pharmaphorum.com/news/eu-regulators-back-lillys-blockbuster-ra-pill/
ema
A new age: the real-world development pathway
Pharma must be prepared to work collaboratively to establish the best benefit-risk profiles and outcomes.
FDA and EMA to work more closely on paediatric drug regulation
FDA and EMA hope to streamline development of paediatric plans.
Novartis’ LEE011 on fast track to challenge Ibrance
US regulator grants fast review for breast cancer drug.
EU regulator begins publishing detailed study data
European Medicines Agency proactively publishes clinical study reports for first time.
Samsung Bioepis files Herceptin biosimilar in EU
South Korean firm trying to copy breast cancer blockbuster.
EU court blocks clinical data release, regulator appeals
EU court to rule on legal row.
US and EU regulators collaborate on rare diseases
Clinical trial design among areas regulators will collaborate on